Pluristem Therapeutics (PSTI) Announces Plan to Expand Research & Development of Radiation Exposure Treatment
Up)
Pluristem Therapeutics, Inc. (Nasdaq: PSTI) today announced that following preliminary discussions with several governmental authorities, it will expand its research and development efforts on an acute radiation exposure treatment. The announcement comes as governments around the world have broadened their search for easily administered and effective radiation countermeasures. Liat Flaishon, MD, PhD, recently appointed Pluristem's Director of Business Development, will lead the company's development efforts.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Pluristem (PSTI) CEO Aberman Sends Letter to Shareholders;
- Nat-Gas Traders Continue to Buy Ahead of Inventory Data
- EIA says US nat-gas stockpiles rose 77 bcf last week
Create E-mail Alert Related Categories
CommoditiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
